Empagliflozin significantly improves myocardial OS damage and myocardial fibrosis in diabetic mice by inhibiting OS and converting the TGF-β/Smad pathway while activating the Nrf2/ARE signaling pathway to suppress neurofibrosis [250]. This evidence concerns the gene TGFB1 and Myocardial fibrosis.